# A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

> **NCT05743010** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Yahong Meditech Co., Ltd aka Asieris** · enrollment: 36 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** APL-1401
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05743010
- **Lead sponsor:** Jiangsu Yahong Meditech Co., Ltd aka Asieris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-26
- **Primary completion:** 2025-03
- **Final completion:** 2025-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743010, "A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05743010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*